Ricerca avanzata

Jaume Pons is the founder of ALX Oncology Ltd.
(founded in 2015) where he holds the title of President, Chief Executive Officer & Director.
He is also the founder of ALX Oncology Holdings, Inc. (founded in 2015) where he holds the title of President, Director & Chief Scientific Officer.
Currently, Dr. Pons is the President & Chief Executive Officer of ALX Oncology, Inc. He is also a Director at Tallac Therapeutics, Inc., Alexo Therapeutics International, Sirpant Therapeutics, and a Venture Partner at venBio Partners LLC.
Additionally, he serves as a Scientific Advisor at LSV Capital Management LLC.
In the past, Dr. Pons worked as the Chief Scientific Officer at Pfizer Inc. from 2007 to 2015.
He also held the position of Chief Scientific Officer at Rinat Neuroscience Corp.
from 2007 to 2015.
Dr. Pons completed his graduate degree at the University of California, Berkeley.
He also holds undergraduate, graduate, and doctorate degrees from Universitat Autònoma de Barcelona.

Jaume Perdigó Pons is currently an Investment Director at Miura Partners SGEIC SA since 2022.
He is also a Board Member at Citrico Global SL and TIERRA - Ingeniería y Paisajismo SL.
In the past, he worked as an Investment Analyst at Suma Capital SGEIC SA from 2016 to 2017 and as an Investment Banking Analyst at Greenhill & Co. Spain Ltd.
from 2017 to 2019.
Mr. Perdigó Pons completed his undergraduate degree at ESADE Business School in 2016.

Alain Pons worked as the Chief Executive Officer at Deloitte et Associes SAS and later at Deloitte SAS from 1980 to 2017.
He also worked as a Director at Constantin Associés SA.